United Therapeutics (NASDAQ:UTHR) announced its earnings results on Wednesday. The biotechnology company reported $2.41 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $2.41, MarketWatch Earnings reports. The business had revenue of $362.00 million for the quarter, compared to analyst estimates of $339.97 million. United Therapeutics had a return on equity of 14.90% and a net margin of 30.04%. The company’s revenue for the quarter was down 3.1% compared to the same quarter last year. During the same period in the previous year, the company earned $3.63 earnings per share.
NASDAQ:UTHR opened at $111.47 on Friday. The firm’s fifty day moving average is $117.48 and its 200-day moving average is $106.45. The company has a debt-to-equity ratio of 0.26, a quick ratio of 8.46 and a current ratio of 7.43. United Therapeutics has a 52 week low of $75.58 and a 52 week high of $127.79. The firm has a market cap of $5.00 billion, a P/E ratio of 11.65 and a beta of 0.86.
A number of equities analysts have commented on UTHR shares. TheStreet downgraded United Therapeutics from a “b” rating to a “c” rating in a research note on Wednesday. HC Wainwright upped their price objective on shares of United Therapeutics from $85.00 to $125.00 and gave the company a “neutral” rating in a research report on Thursday, June 25th. ValuEngine cut shares of United Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Thursday, July 2nd. Cowen reissued a “buy” rating and issued a $145.00 target price on shares of United Therapeutics in a research note on Friday, June 12th. Finally, Zacks Investment Research raised shares of United Therapeutics from a “hold” rating to a “buy” rating and set a $128.00 price objective on the stock in a research note on Sunday, May 3rd. Three equities research analysts have rated the stock with a sell rating, one has issued a hold rating and eight have given a buy rating to the stock. United Therapeutics has an average rating of “Hold” and a consensus price target of $138.10.
United Therapeutics Company Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
Further Reading: How much can an individual set aside as a catch-up contribution?
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.